HIF1a regulates single differentiated glioma cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential under hypoxia

**Supplementary Materials** 





В



**Supplementary Figure 1: Dedifferentiation can be induced under hypoxia conditions.** (A) We recorded cell status under hypoxia and normoxia on day 0, 3, 7, 14 and 21 and found hypoxia  $(1\%O_2)$  induced the formation of neurospheres by Single CD133 CD15 NESTIN GL261 or U87 cell, but no neurosphere formed under normoxia  $(21\%O_2)$  (B) Representative pictures of irregular, non-adherent and loose aggregates under normoxia and representative pictures of induced neurospheres under hypoxia.

















**Supplementary Figure 2: Hypoxia improved the expression of stem cell markers in the detection of immunofluorescence.** To improve the accuracy and set the detection in the same background in immunofluorescence, we did double immunofluorescent labeling of f-actin and stem cell markers for U87 CD133 CD15 NESTIN cells cultured in hypoxia and normoxia and the results showed there were no difference for the expression of f-actin between hypoxia and normoxia group ( $^{#}P > 0.05$ , Paired-samples *T* Test); however, significant higher expression were demonstrated for SOX-2, OCT-4, KLF-4, Nanog, CD133, CD15, NESTIN and ABCG2 in the cells under hypoxia compared with the expression of stem cell markers of normoxia treated cells ( $^{*}P < 0.05$ , Paired-samples *T* Test).



С









Con (3×10<sup>4</sup> Cells)

Vector (3×10<sup>4</sup> Cells)

HIF1a-ShRNA (3×10<sup>4</sup> Cells)



Supplementary Figure 3: The influence of HIF1a on tumor formation. (A) Immunohistochemical staining demonstrated there was HIF1a expression in tumor sample collected from mice fed in 10%O,. (B) Western-blot showed HIF1a expression of tumor sample collected from mice fed in 10%O, was about three times higher than control including normal brain tissues and tumor sample obtained from normoxia  $(21\%O_2)$  raised mice. (C) RT-PCR showed there was higher expression of HIF1 $\alpha$  in the tumor sample collected from mice fed in 10%O<sub>2</sub>, and no differences was detected between normal brain tissues and tumor sample obtained from normoxia (21%O<sub>2</sub>) raised mice. (D-E) GL261-luc HIF1α-ShRNA cells seeded group raised in 10%O, showed a smaller size of tumor formation than control and the quantitative value of bioluminescence was significantly decreased (\*P < 0.001, Paired-samples T Test). (F) The survival rate of GL261 HIF1 $\alpha$ -ShRNA cells seeded group was higher than control (\*P > 0.05, \*\*P < 0.05, Log-rank Test)

Supplementary Table 1: Single CD133-CD15-NESTIN- cell seeded and neurospheres formed under normoxia or hypoxia

Α

Normoxia (21% O <sub>2</sub> )								
		L0	3d		74	14.1	21.1	d21
	trials 0d seeding		Survived cell	aggregates	aggregates	aggregates	aggregates	aggregates /d3 Survived
	1	240	142	0	2	5	9	6.34
GL261	2	256	161	0	0	4	7	4.35
(3 plates/	3	252	157	0	0	2	7	4.46
trial)	mean	249.33	153.33	0.00	0.67	3.67	7.67	5.05
	SE	8.33	10.02	0.00	1.15	1.53	1.15	1.12
	1	230	137	0	0	0	0	0.00
U87	2	261	155	0	0	1	2	1.29
(3 plates/	3	238	152	0	0	1	4	2.63
trial)	mean	243.00	148	0.00	0.00	0.67	2.00	1.31
	SE	16.09	9.64	0.00	0.00	0.58	2.00	1.32

#### B

Hypoxia (1% O<sub>2</sub>)

	b0		3d		7d	14d	21d	d21
	trials	seeding	Survived cell	Spheres	Spheres	Spheres	Spheres	Spheres /d3 Survived
	1	252	149	1	41	99	145	97.32
GL261	2	272	165	2	57	102	165	100.00
(3 plates/ trial)	3	241	152	2	39	92	135	88.80
	mean	255.00	155.33	1.67	45.67	97.67	148.33	95.38
	SE	15.72	8.50	0.58	9.87	5.13	15.28	5.83
	1	261	144	0	52	106	142	98.61
U87	2	254	156	1	49	99	156	100.00
(3 plates/	3	254	154	3	43	92	152	98.70
trial)	mean	256.33	151.33	1.33	48.00	99.00	150.00	99.10
	SE	4.04	6.43	1.53	4.58	7.00	7.21	0.78

Under hypoxia, >60% CD133<sup>-</sup>CD15<sup>-</sup>NESTIN<sup>-</sup> cells survived after exposure 3d for both GL261 and U87 glioma cells; and most surviving cells (95.38%±5.83 from GL261 and 99.10%±0.78 from U87) formed neurospheres at 21 d. However, under normoxia, only 5.05%±1.12 from GL261 and 1.31%±1.32 from U87 cells formed sparse, irregular and non-adherent aggregates.

Sup	olementary	Table 2:	Numerical	value of t	he Fluc-	Viable	glioma ce	lls in	groups
							<b>B</b>		<b>A</b>

Tumor Size Group	5d	10d	15d	20d	25d
1	$\begin{array}{c} 8.280 \times 10^{4} \\ 2.819 \times 10^{4} \\ 2.101 \times 10^{4} \end{array}$	$\begin{array}{c} 31.840 \times 10^{4} \\ 8.718 \times 10^{4} \\ 2.209 \times 10^{4} \end{array}$	$\begin{array}{c} 4.211 \times 10^{4} \\ 6.185 \times 10^{4} \\ 29.810 \times 10^{4} \end{array}$	$\begin{array}{c} 523.100 \times 10^{4} \\ 294.200 \times 10^{4} \\ 156.100 \times 10^{4} \end{array}$	$\begin{array}{c} 399.000 \times 10^{4} \\ 334.200 \times 10^{4} \\ 62.770 \times 10^{4} \end{array}$
2	$\begin{array}{c} 1.814 \times 10^{4} \\ 1.636 \times 10^{4} \\ 1.613 \times 10^{4} \end{array}$	$3.272 \times 10^4$ $2.761 \times 10^4$ $4.046 \times 10^4$	$\begin{array}{c} 0.775 \times 10^{4} \\ 3.756 \times 10^{4} \\ 4.593 \times 10^{4} \end{array}$	$2.940 \times 10^4$ $1.957 \times 10^4$ $2.844 \times 10^4$	$\begin{array}{c} 1.086 \times 10^{4} \\ 0.976 \times 10^{4} \\ 1.246 \times 10^{4} \end{array}$
3	$\begin{array}{c} 2.624 \times 10^{4} \\ 2.678 \times 10^{4} \\ 4.271 \times 10^{4} \end{array}$	$\begin{array}{c} 8.684 \times 10^{4} \\ 14.990 \times 10^{4} \\ 14.230 \times 10^{4} \end{array}$	$\begin{array}{c} 47.140 \times 10^{4} \\ 1.466 \times 10^{4} \\ 31.600 \times 10^{4} \end{array}$	$\begin{array}{c} 87.690 \times 10^{4} \\ 12.810 \times 10^{4} \\ 3.273 \times 10^{4} \end{array}$	$\begin{array}{c} 0.416 \times 10^{4} \\ 0.551 \times 10^{4} \\ 2.795 \times 10^{4} \end{array}$
4	$\begin{array}{c} 3.946 \times 10^{4} \\ 4.757 \times 10^{4} \\ 6.010 \times 10^{4} \end{array}$	$\begin{array}{c} 19.680 \times 10^{4} \\ 20.880 \times 10^{4} \\ 25.540 \times 10^{4} \end{array}$	$\begin{array}{c} 99.870 \times 10^{4} \\ 30.450 \times 10^{4} \\ 90.930 \times 10^{4} \end{array}$	$\begin{array}{c} 126.000 \times 10^{4} \\ 19.990 \times 10^{4} \\ 536.500 \times 10^{4} \end{array}$	$\begin{array}{c} 545.500 \times 10^{4} \\ 258.100 \times 10^{4} \\ 11.390 \times 10^{4} \end{array}$

Group 1: C57 Mouse (21%O<sub>2</sub>); GL261 Cell (1%O<sub>2</sub>) Group 2: C57 Mouse (21%O<sub>2</sub>); GL261 Cell (21%O<sub>2</sub>) Group 3: C57 Mouse (21%O<sub>2</sub>); GL261 Cell (21%O<sub>2</sub>)

STRATEGY 1

Group 3: C57 Mouse (21%O<sub>2</sub>); GL261 Cell (21%O<sub>2</sub>) Group 4: C57 Mouse (10%O<sub>2</sub>); GL261 Cell (21%O<sub>2</sub>)  $\}$ 

STRATEGY 2

Two different strategies were used to investigate the effect of hypoxia-induced GSCs on tumorigenesis in vivo. STRATEGY 1 (Group1-Group2): 14d hypoxia (1%)-induced neurospheres–derived GL261 cells (Group1 10<sup>4</sup>) or normoxia (21%)-derived GL261 CD133 CD15 NESTIN cells (Group2 10<sup>4</sup>) were injected into the brains of adult female C57 mice and these mice were raised under normoxia (21% O<sub>2</sub>). There were no significant differences on tumor volume between the two groups on day 5; but after 25d, tumors were detected in group 1 with magnitude orders more than 10<sup>6</sup>. For group 2 the orders of magnitude were around 10<sup>4</sup>. STRATEGY 2 (Group3-Group4): the mice in group 3 (3 × 10<sup>4</sup>) underwent similar changes as group 2 in strategy 1, and group 4 was injected with differentiated CD133 CD15 NESTIN Gl261 cells (3 × 10<sup>4</sup>) but raised under 10% O<sub>2</sub> at 25 d, tumors were detected in group 4 with magnitude orders greater than 10<sup>6</sup>. For group 3 the orders of magnitude were less than 10<sup>4</sup> and only reached to 4,161.

# Supplementary Table 3: Single CD133<sup>-</sup>CD15<sup>-</sup>NESTIN<sup>-</sup> cell seeded and neurospheres formed under hypoxia contained FBS or not

## Α

### 1%O<sub>2</sub>(No FBS)

			3d		7.4	14d	<b>21</b> d	d21 aggragatos
	trials	0d seeding	Survived cell	aggregates	aggregates	aggregates	aggregates	/d3 Survived
	1	263	102	0	1	4	9	8.82
GL261	2	251	95	0	0	2	5	5.26
	3	257	92	0	0	0	1	1.09
	mean	257	96.00	0	0.33	2.00	5.00	5.06
	SE	6	5.13	0	0.58	2	4	3.87
	1	272	113	1	1	4	7	6.19
	2	251	105	0	2	3	5	4.76
U87	3	263	103	0	0	3	5	4.85
	mean	262.00	107	0.33	1.00	3.33	5.67	5.27
	SE	10.54	5.29	0.58	1.00	0.58	1.15	0.80

#### B

1%O <sub>2</sub> (Contained FBS)								
			3d		74	144	21d Spheres	d21 Spheres /d3 Survived
	trials 0d seeding	Survived cell	Spheres	Spheres	Spheres			
GL261	1	252	149	1	41	99	145	97.32
	2	272	165	2	57	102	165	100.00
	3	241	152	2	39	92	135	88.80
	mean	255.00	155.33	1.67	45.67	97.67	148.33	95.38
	SE	15.72	8.50	0.58	9.87	5.13	15.28	5.83
	1	261	144	0	52	106	142	98.61
	2	254	156	1	49	99	156	100.00
U87	3	254	154	3	43	92	152	98.70
	mean	256.33	151.33	1.33	48.00	99.00	150.00	99.10
	SE	4.04	6.43	1.53	4.58	7.00	7.21	0.78

The clone formation rates (spheres/d3 viable cells) were  $5.06\% \pm 3.87$  from GL261 and  $5.27\% \pm 0.80$  from U87 cells suspended in medium without FBS following hypoxia treatment 21d. However, the clone formation rates (spheres/d3 viable cells) of GL261 and U87 suspended with DMEM/F12+10% FBS were more than 95% after hypoxia treatment 21 d.

# Supplementary Table 4: Single U87 CD133-CD15-NESTIN-HIF1α-ShRNA cell seeded and spheres formed under hypoxia

	<u></u>	<u> </u>	3d		1			d21
I	trials	0d seeding	Survived cell	Spheres	7d Spheres	14d Spheres	21d Sphere	es Spheres /d3 Survived
	1	243	134	6	52	92	132	98.51
	2	234	144	5	61	97	144	100.00
Ι	3	219	133	9	49	85	129	96.99
	mean	232.00	137.00	6.67	54.00	91.33	135	98.5
	SE	12.12	6.08	2.08	6.24	6.03	7.94	1.51
	1	257	155	9	61	104	148	95.48
	2	229	127	6	55	89	125	98.43
II	3	237	139	11	45	82	137	98.56
	mean	241.00	140.00	8.67	53.67	91.67	136.67	97.49
	SE	14.42	14.05	2.52	8.08	11.24	11.50	1.74
3d								
				3d		141	01.1	
	trials	0d seedin	g Surviv	3d ved G	7d	14d	21d	d21 Spheres
	trials	0d seedin	g Surviv cell	3d ved Sphe	7d res Spheres	14d Spheres	21d Spheres	d21 Spheres /d3 Survived
[]	trials 1	<b>0d seedin</b> 253	g Surviv cell	<b>3d</b> Ved Sphe	res 7d 23	14d Spheres	21d Spheres 86	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99
	<b>trials</b> 1 2	<b>0d seedin</b> 253 247	<b>g</b> Surviv cell 141 136	<b>3d</b> <b>yed</b> <b>Sphe</b> 1 3	7d           Spheres           23           19	<b>14d</b> <b>Spheres</b> 53 58	<b>21d</b> <b>Spheres</b> 86 92	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99 67.65
III	<b>trials</b> 1 2 3	<b>0d seedin</b> 253 247 257	g Surviv cell 141 136 129	<b>3d</b> <b>yed</b> <b>Sphe</b> 1 3 7	7d           Spheres           23           19           12	<b>14d</b> <b>Spheres</b> 53 58 61	<b>21d</b> <b>Spheres</b> 86 92 80	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99 67.65 62.02
III	trials 1 2 3 mean	<b>0d seedin</b> 253 247 257 252.00	g Surviv cell 141 136 129 135.0	<b>3d</b> <b>yed</b> <b>Sphe</b> 1 3 7 0 3.6'	7d           Spheres           23           19           12           18.00	14d           Spheres           53           58           61           57.33	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b>	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99 67.65 62.02 <b>63.55</b>
III	trials 1 2 3 mean SE	<b>0d seedin</b> 253           247           257           252.00           5.03	g Surviv cell 141 136 129 135.0 6.03	3d           yed         Sphe           1         3           7         3.6°           3.00         3.00	7d           Spheres           23           19           12           18.00           5.57	14d           Spheres           53           58           61           57.33           4.04	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b> 6.00	d21 Spheres /d3 Survived 60.99 67.65 62.02 63.55 3.59
III	trials 1 2 3 mean SE 1	<b>0d seedin</b> 253           247           257           252.00           5.03           272	g Surviv cell 141 136 129 135.0 6.03 137	3d           yed         Sphe           1         3           7         3.66           3.00         0	7d Spheres           23           19           12           18.00           5.57           0	14d           Spheres           53           58           61           57.33           4.04           1	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b> 6.00 2	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99 67.65 62.02 <b>63.55</b> 3.59 1.46
III	trials       1       2       3       mean       SE       1       2	<b>0d seedin</b> 253           247           257           252.00           5.03           272           261	g Surviv cell 141 136 129 135.0 6.03 137 119	3d           yed         Sphe           1         3           7         3.6°           3.0°         0           0         3.6°           0         0           0         0	7d           Spheres           23           19           12           18.00           5.57           0           1	14d           Spheres           53           58           61           57.33           4.04           1           1	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b> 6.00 2 2 2	<b>d21 Spheres</b> / <b>d3 Survived</b> 60.99 67.65 62.02 <b>63.55</b> 3.59 1.46 1.68
III IV	trials 1 2 3 mean SE 1 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	<b>0d seedin</b> 253           247           257           252.00           5.03           272           261           243	g Surviv cell 141 136 129 135.0 6.03 137 119 112	3d           yed         Sphe           1         3           7         3.66           3.00         0           0         3.66           0         0           0         0           0         0           0         0	7d Spheres           23           19           12           18.00           5.57           0           1           2	14d           Spheres           53           58           61           57.33           4.04           1           2	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b> 6.00 2 2 2 3	<b>d21 Spheres</b> /d3 Survived 60.99 67.65 62.02 <b>63.55</b> 3.59 1.46 1.68 2.68
III IV	trials         1         2         3         mean         SE         1         2         3         mean         3         mean         3         mean	Od seedin           253           247           257           252.00           5.03           272           261           243           259.00	g Surviv cell 141 136 129 135.0 6.03 137 119 112 123.0	3d           yed         Sphe           1         3           7         3.6'           3.00         0           0         3.6'           0         0.00           0         0.00	7d           Spheres           23           19           12           18.00           5.57           0           1           2           1.00	14d           Spheres           53           58           61           57.33           4.04           1           2           1.33	<b>21d</b> <b>Spheres</b> 86 92 80 <b>86.00</b> 6.00 2 2 2 3 3 <b>2.33</b>	d21 Spheres /d3 Survived 60.99 67.65 62.02 63.55 3.59 1.46 1.68 2.68 1.94

I: U87 Not-Targeted HIF1 $\alpha$  (1%O<sub>2</sub>);

II: U87 HIF1 $\alpha$ -Vector 3(1%O<sub>2</sub>);

III: U87 HIF1 $\alpha$ -ShRNA 3(1% $O_2$ );

IV: Digoxin (1%O<sub>2</sub>)

The neurosphere formation rate of the HIF1 $\alpha$ -ShRNA- or digoxin-treated U87 cells was substantially lower than that of the controls. The numerical value was  $63.55 \pm 3.59\%$  from the single CD133<sup>-</sup>CD15<sup>-</sup>NESTIN<sup>-</sup>HIF1 $\alpha$ -ShRNA U87 cells and  $1.94 \pm 0.65\%$  from digoxin treatment U87 cells.

	upstream (5'→3')	downstream $(5' \rightarrow 3')$
Human SOX-2	GGAGGGGTGCAAAAGAGGAGAG	TCCCCCAAAAAGAAGTCCAGG
Human OCT-4	CCCGCCGTATGAGTTCTGTGG	CCGGGTTTTGCTCCAGCTTCTC
Human KLF-4	GGCTGCGGCAAAACCTACAC	CGGGCGAATTTCCATCCAC
Human Nanog	CCGCGCCCTGCCTAGAAAAGAC	AGCCTCCCAATCCCAAACAATACG
Human CD133	GCCCCCAGGAAATTTGAGGAAC	GCTTTGGTATAGAGTGCTCAGTGATTG
Human CD15	TGGGCAGGCTGGTCTTGAACT	CACGGCGGCTCACACCTGTA
Human NESTIN	GCCCCTGGTGGAAGATGATG	GCCCTGAACCCTCTTTGCCTC
Human ABCG2	TAGTGAGGAAAGTTCCTGTC	AGCTCAGTTAACTCCTGTAAG
Human HIF1α	CCCTCACCCACAAAAATTAC	GGGACTATTAGGCTCAGGTGAAC
Human VEGF	TTCGGGAACCAGATCTCTCACC	CGGACCCAAAGTGCTCTGC
Mouse SOX-2	GGGGGCAGCGGCGTAAGATG	CCCGCTCGCCATGCTGTTC
Mouse OCT-4	GCCCGGAAGAGAAAGCGAAC	GGGGCAGAGGAAAGGATACAG
Mouse KLF-4	CCGGCCCAACACACACGACTTC	GAACCCGGTGGCATGAGCTCTTG
Mouse Nanog	GCCCAGCTGTGTGCACTCAAGG	GGCTTCCAGATGCGTTCACCAGATA
Mouse CD133	CCGCGATGGACTCTGCTGTTAATG	GGGCACAGTCTCAACATCGTCGTATAC
Mouse CD15	ATCGGGCTGCTGCACACTG	AGCGGAAGTAGCGGCGATAGAC
Mouse NESTIN	GCCCAAGCAGGTGAACAAGACT	CAGCCCTTGCATTCCAGAGTCT
Mouse ABCG2	AGAAACTCTTCATACATGAGTACA	AAGTGTTGCTACAGACACCACAC
Mouse HIF1a	AGCCTTAACCTGTCTGCCACTTTG	GGGCACAGTCTCAACATCGTCGTATAC
Mouse VEGF	CCGGTTTAAATCCTGGAGCGTTC	CACCGCCTTGGCTTGTCACA
β-actin	ACCCGCCGCCAGCTCACC	GGGGGGCACGAAGGCTCATC

## **Supplementary Table 5: the primer sequences of stem cell markers**